Clinical Trial Update: [68Ga]Ga-FAPI Total Body PET/CT for Better and Faster Imaging in Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the performance of Gallium-68 labeled FAPI PET/CT for cancer imaging, including patients with malignant melanoma stage IV.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• Ga-68-FAPI (gallium-68-labeled fibroblast activation protein inhibitor)

Snippet

Sponsor: Barbara Malene Fischer | Conditions: Malignant Melanoma Stage IV | Phase 2 | Status: RECRUITING